Estimating the Population Benefits and Costs of Rituximab Therapy in the United States from 1998 to 2013 Using Real-World Data

BACKGROUND: Rituximab was approved in 1997 and is regularly one of the largest drug expenditures for Medicare; however, its benefits and costs have not been estimated from a population perspective. OBJECTIVES: To estimate both the clinical and the economic outcomes of rituximab for its approved hema...

Descripción completa

Detalles Bibliográficos
Autores principales: Danese, Mark D., Reyes, Carolina M., Gleeson, Michelle L., Halperin, Marc, Skettino, Sandra L., Mikhael, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4795096/
https://www.ncbi.nlm.nih.gov/pubmed/26759977
http://dx.doi.org/10.1097/MLR.0000000000000486

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4795096/
https://www.ncbi.nlm.nih.gov/pubmed/26759977
http://dx.doi.org/10.1097/MLR.0000000000000486

Ejemplares similares